Email this article Cytotoxic treatment complications in the patients with lung cancer
- Authors: Popova ME1, Popova ME1
-
Affiliations:
- Issue: Vol 13, No 1-2 (2013)
- Pages: 127-130
- Section: Articles
- URL: https://aspvestnik.ru/2410-3764/article/view/24755
- DOI: https://doi.org/10.17816/2072-2354.2013.0.1-2.127-130
- ID: 24755
Cite item
Full Text
Abstract
Lung cancer - the leading cause of cancer mortality in most developed countries. Despite of the extensive development of the prevention, diagnosis and treatment, lung cancer has the highest incidence of all cancers among men and is the consistent upward trend in the incidence among women. Chemotherapy is one of the main methods of the treatment required for the most patients with lung cancer. A side effect of cytotoxic drugs is often limited. For the majority of side effects of anticancer agents corresponding grade 3 toxicity, and more, is an indication to stop chemotherapy and requires intensive treatment cover. Resuming chemotherapy depends on the completeness and rate of elimination of side effects and complications, which in turn, worsens the prognosis.
Full Text
Осложнения цитостатического лечения у больных раком легких×
References
- Давыдов, М.И. Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2008 г // Вестник РОНЦ им. Н.Н.Блохина РАМН // - 2010. - Т.21, № 2(80), прил. 1.- С.52-54
- Бычков М.Б. Немелкоклеточный рак лёгкого // Руководство по химиотерапии опухолевых заболеваний. / Под ред. Переводчиковой Н.И. - 3-е изд. - М.: Практическая медицина, 2011. - С. 141.
- Кондратьев В.Б., Карасёва Н.А. Лечение и профилактика осложнений химиотерапии препаратами платины и таксанами // Практическая онкология. – 2000. - № 3. – С. 38-42.
- Giaccone G, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. clin. oncol. 1998;16:2133-2141.
- Langer C.J. et al. Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. Semin. oncol. - 1999; 26 (Suppl. 4):12-18.
- Belani C.P., et al. Docetaxel and cisplatin in patients with advanced non small cell lung (NSCLC): a multicentre phase II trail. Clin. lung. cancer. - 1999; 1:144-150.
- Fossella F. et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J. clin. oncol. - 2003; 21:3016-3024.
- Чу Вит Э., Де Вит-мл. В. Химиотерапия злокачественных новообразований. – М.: Практика, 2008. – 448с.
- Королева И.А., Копп М.В. Профилактика тошноты и рвоты при проведении цитостатической терапии у взрослых // Фарматека. – 2010. – № 6. – С. 30-35.
Supplementary files
